The Combination of Atezolizumab and Bevacizumab Versus Lenvatinib as a First-Line Systemic Therapy for Treatment of Hepatocellular Carcinoma: A Real-World Comparison
Introduction: Atezolizumab plus bevacizumab (AB) and lenvatinib (LEN) demonstrate non-inferior survival compared with sorafenib for first-line treatment of unresectable hepatocellular carcinoma (HCC) but have not been directly compared. We retrospectively compared survival outcomes between patients treated with AB and...